| Bioactivity | CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research[1]. |
| Target | IC50: 1.38 μM (TMPRSS2), IC50: 2.13/64.07 nM (CTSL/CTSB) |
| Invitro | CTSLCTSB-IN-1 (10-3-105 nM,1h) 在临床分离的 SARS-CoV-2 δ 株或 omicron BA.2 株感染的 Calu-3 细胞中显示出显著的抗病毒作用[1]。 0 --> CTSL/B-IN-1 相关抗体: |
| Name | CTSL/B-IN-1 |
| Formula | C41H47N7O6S |
| Molar Mass | 765.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Haitao Yang, et al. Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry. Nat Commun,.2023，14，7574. |